My final question is for Dr. Annan.
You've described Genome Canada's work in looking at viral mutations and also at human genetics to see if there are particular tendencies to be susceptible to various viral mutations, etc. You're obviously doing this for COVID-19. Have you done similar work for other viruses, and has it led to some sort of clinical outcome that was successful?